Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.
about
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.The multifaceted role of CD146/MCAM in the promotion of melanoma progression.Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression.
P2860
Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.
@en
type
label
Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.
@en
prefLabel
Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.
@en
P2093
P2860
P356
P1433
P1476
Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.
@en
P2093
Andrea L George
Jan Geliebter
Marc Wallack
Raj K Tiwari
Robert Suriano
Shilpi Rajoria
P2860
P304
P356
10.7150/JCA.6625
P577
2013-06-19T00:00:00Z